Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Methodological Challenges When Comparing Demographic and Clinical Characteristics of International Observational Registries.
Verstappen SM, Askling J, Berglind N, Franzen S, Frisell T, Garwood C, Greenberg JD, Holmqvist M, Horne L, Lampl K, Michaud K, Nyberg F, Pappas DA, Reed G, Symmons DP, Tanaka E, Tran TN, Yamanaka H, Ho M. Verstappen SM, et al. Among authors: horne l. Arthritis Care Res (Hoboken). 2015 Dec;67(12):1637-45. doi: 10.1002/acr.22661. Arthritis Care Res (Hoboken). 2015. PMID: 26201948 Free article.
Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approach.
Nyberg F, Askling J, Berglind N, Franzén S, Ho M, Holmqvist M, Horne L, Lampl K, Michaud K, Pappas DA, Reed G, Symmons D, Tanaka E, Tran TN, Verstappen SM, Wesby-van Swaay E, Yamanaka H, Greenberg JD. Nyberg F, et al. Among authors: horne l. Pharmacoepidemiol Drug Saf. 2015 Nov;24(11):1121-32. doi: 10.1002/pds.3854. Epub 2015 Aug 25. Pharmacoepidemiol Drug Saf. 2015. PMID: 26303866
How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries.
Askling J, Berglind N, Franzen S, Frisell T, Garwood C, Greenberg JD, Ho M, Holmqvist M, Horne L, Inoue E, Michaud K, Nyberg F, Pappas DA, Reed G, Tanaka E, Tran TN, Verstappen SM, Yamanaka H, Wesby-van Swaay E, Symmons D. Askling J, et al. Among authors: horne l. Ann Rheum Dis. 2016 Oct;75(10):1789-96. doi: 10.1136/annrheumdis-2015-208105. Epub 2015 Nov 30. Ann Rheum Dis. 2016. PMID: 26621482
Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular disease.
Michaud K, Berglind N, Franzén S, Frisell T, Garwood C, Greenberg JD, Ho M, Holmqvist M, Horne L, Inoue E, Nyberg F, Pappas DA, Reed G, Symmons D, Tanaka E, Tran TN, Verstappen SM, Wesby-van Swaay E, Yamanaka H, Askling J. Michaud K, et al. Among authors: horne l. Ann Rheum Dis. 2016 Oct;75(10):1797-805. doi: 10.1136/annrheumdis-2015-208698. Epub 2016 Feb 8. Ann Rheum Dis. 2016. PMID: 26857699
Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study.
Pappas DA, Nyberg F, Kremer JM, Lampl K, Reed GW, Horne L, Ho M, Onofrei A, Malaviya AN, Rillo OL, Radominski SC, Gal J, Gibofsky A, Popkova TV, Laurindo L, Kerzberg EM, Zahora R, Pons-Estel BA, Curtis JR, Furst DE, Greenberg JD. Pappas DA, et al. Among authors: horne l. Clin Rheumatol. 2018 Sep;37(9):2331-2340. doi: 10.1007/s10067-018-4113-3. Epub 2018 Apr 25. Clin Rheumatol. 2018. PMID: 29696436
Disease Control, Health Resource Use, Healthcare Costs, and Predictors in Gout Patients in the United States, the United Kingdom, Germany, and France: A Retrospective Analysis.
Morlock R, Chevalier P, Horne L, Nuevo J, Storgard C, Aiyer L, Hines DM, Ansolabehere X, Nyberg F. Morlock R, et al. Among authors: horne l. Rheumatol Ther. 2016 Jun;3(1):53-75. doi: 10.1007/s40744-016-0033-3. Epub 2016 May 25. Rheumatol Ther. 2016. PMID: 27747520 Free PMC article.
Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies.
Lo Re V 3rd, Haynes K, Ming EE, Wood Ives J, Horne LN, Fortier K, Carbonari DM, Hennessy S, Cardillo S, Reese PP, Reddy KR, Margolis D, Apter A, Kimmel SE, Roy J, Freeman CP, Razzaghi H, Holick CN, Esposito DB, Van Staa TP, Bhullar H, Strom BL. Lo Re V 3rd, et al. Among authors: horne ln. Pharmacoepidemiol Drug Saf. 2012 Nov;21(11):1202-15. doi: 10.1002/pds.3318. Epub 2012 Jul 5. Pharmacoepidemiol Drug Saf. 2012. PMID: 22763953
Challenges facing drug utilization research in the Latin American region.
Salas M, Lopes LC, Godman B, Truter I, Hartzema AG, Wettermark B, Fadare J, Burger JR, Appenteng K, Donneyong M, Arias A, Ankrah D, Ogunleye OO, Lubbe M, Horne L, Bernet J, Gómez-Galicia DL, Del Carmen Garcia Estrada M, Oluka MN, Massele A, Alesso L, Herrera Comoglio R, da Costa Lima E, Vilaseca C, Bergman U. Salas M, et al. Among authors: horne l. Pharmacoepidemiol Drug Saf. 2020 Nov;29(11):1353-1363. doi: 10.1002/pds.4989. Epub 2020 May 17. Pharmacoepidemiol Drug Saf. 2020. PMID: 32419226 Free article. Review.
125 results